Physician profile
Oya Tugal
NPI 1093707838
$48,507.50
in general payments reported to CMS, 2019-2025
27 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $540 · 2021: $12K · 2022: $10K · 2023: $20K · 2024: $6,268 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Honoraria: $9,000 · Travel and Lodging: $3,999 · Food and Beverage: $2,170 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,575.00 |
| Honoraria | $9,000.00 |
| Travel and Lodging | $3,998.93 |
| Food and Beverage | $2,170.05 |
| Education | $179.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $15,383.76 | 2020-2022 | |
| Octapharma USA, INC. | $14,446.20 | 2019-2023 | Nuwiq, Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) |
| Pfizer INC. | $13,237.17 | 2023-2025 | |
| Csl Behring | $3,423.35 | 2019-2024 | Hemgenix, Haegarda, Kcentra |
| Amgen INC. | $310.79 | 2021-2023 | Blincyto |
| Genentech USA, INC. | $173.36 | 2019-2024 | Hemlibra |
| Genzyme Corporation | $162.57 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $156.64 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.02 | 2020-2024 | Advate, Takhzyro |
| Alexion Pharmaceuticals, INC. | $150.12 | 2023-2024 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $148.26 | 2019-2021 | |
| Sobi, INC | $110.79 | 2020-2025 | |
| Astellas Pharma US INC | $99.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $91.08 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $88.34 | 2023-2024 | Jornay Pm |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $84.36 | 2024-2025 | Pyrukynd |
| Grifols USA, LLC | $57.58 | 2022-2024 | Alphanate, Gamunex-C |
| Servier Pharmaceuticals LLC | $43.58 | 2023-2024 | |
| Bio Products Laboratory USA, INC. | $39.37 | 2020-2022 | |
| Aveo Pharmaceuticals, INC. | $31.67 | 2021 | |
| Uswm, LLC | $30.61 | 2024 | Iwilfin |
| Biocon Biologics INC | $22.60 | 2024 | Fulphila |
| Allergan, INC. | $20.04 | 2019 | |
| Novo Nordisk INC | $17.48 | 2022 | |
| Dova Pharmaceuticals | $14.37 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.39 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oya Tugal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.